Pharma’s Almanac’s Cynthia Challener, Ph.D., discusses the current state of the biosimilars market, the arguments for and against automatically considering biosimilars to be interchangeable, and the regulatory challenges to their adoption and developments to remove inefficiencies in their approval.
.svg)
